SequelSEC

Lipocine Inc. LPCN

Pharmaceutical Preparations · CIK 0001535955 · Fiscal year ends 1231

Revenue
$1.98M
Fiscal year ended 2025-12-31
Operating income
-$10.37M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$16.40MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$2.25Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue8.3×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.1×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth-82.3%15th
Current ratio6.68x68th
R&D / revenue434.3%64th
Net margin-487.1%38th
SBC / revenue12.3%40th
Operating margin-524.7%41th

Lipocine Inc. (LPCN) reported revenue of $1.98M and net income of -$9.63M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Lipocine Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Lipocine Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$1.98M$11.20M-$2.85M$500.00K$16.14M$0$164.99K$428.03K$0$0
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$10.37M-$1.16M-$17.93M-$12.12M$3.15M-$18.00M-$12.90M-$11.33M-$21.22M-$19.19M
Net income-$9.63M$8.35K-$16.35M-$10.76M-$634.40K-$20.96M-$13.01M-$11.66M-$20.98M-$18.97M
Research & development$8.58M$7.35M$10.18M$8.56M$7.67M$9.75M$7.47M$6.46M$11.00M$8.08M
Weighted-average diluted sharesshares 5.71Mshares 5.42Mshares 5.27Mshares 5.26Mshares 87.62Mshares 55.69Mshares 25.88Mshares 21.35Mshares 20.05Mshares 18.26M
Pretax income-$9.63M$9.03K-$16.35M-$10.76M-$634.20K-$20.96M-$13.01M-$11.66M-$20.98M-$18.97M
Income tax expense$200$681$755$681$200$200$200$700$700$752
Diluted EPS$-1.69Unavailable$-3.14$-2.15$-0.01$-0.38$-0.50$-0.55$-1.05$-1.04
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$3.76M$5.00M$4.90M$4.06M$5.33M$8.25M$5.60M$5.29M$10.21M$10.38M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Lipocine Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalents$5.21M$6.21M$4.77M$3.15M$2.95M$19.22M$9.73M$8.08M$3.21M$5.56M
Total assets$17.01M$22.51M$23.00M$37.54M$52.48M$25.35M$19.66M$20.85M$25.33M$27.34M
Current assets$16.88M$22.32M$22.86M$34.14M$46.38M$25.33M$19.63M$20.81M$25.22M$27.21M
Total liabilities$2.53M$1.51M$2.63M$1.91M$6.91M$10.01M$13.37M$11.42M$6.35M$1.33M
Current liabilities$2.53M$1.51M$2.63M$1.68M$5.62M$6.58M$4.96M$4.49M$6.35M$1.33M
Total equity incl. NCI$14.48M$21.00M$20.37M$35.63M$45.57M$15.34M$6.29M$9.43M$18.98M$26.02M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailable$1.67M$2.26M$3.81M$6.93M$0Unavailable
Accounts payable$971.82K$271.70K$1.40M$600.39K$1.29M$1.60M$1.18M$671.28K$598.07K$245.92K

Cash flow

Lipocine Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow-$9.76M-$1.22M-$11.87M-$11.97M-$4.41M-$15.30M-$11.67M-$12.08M-$16.70M-$18.28M
Capital expendituresUnavailable$90.09K$13.17K$133.83K$7.59KUnavailableUnavailable$0$0$59.65K
Investing cash flow$5.89M$2.45M$13.08M$14.29M-$43.78M$3.89M$3.00M$11.29M$3.13M$3.23M
Financing cash flow$2.87M$209.34K$404.57K-$2.13M$26.92M$20.90M$10.32M$10.65M$11.23M$605.87K
Net change in cash-$1.00M$1.43M$1.62M$197.94K-$21.27M$9.49MUnavailable$9.87M-$2.35M-$14.45M
Stock-based compensation$242.50K$408.55K$654.44K$636.14K$603.95K$1.37M$1.04M$1.46M$2.72M$2.37M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$60.78K$41.11K$28.66K$9.45K$380$3.55K$15.44K$18.60K$28.37K$31.96K

Derived

Lipocine Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flowUnavailable-$1.31M-$11.88M-$12.10M-$4.42MUnavailableUnavailableUnavailable-$16.70M-$18.34M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-524.7%-10.3%Unavailable-2423.9%19.5%Unavailable-7818.8%-2646.0%UnavailableUnavailable
FCF marginUnavailable-11.7%Unavailable-2420.5%-27.4%UnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue12.3%3.6%Unavailable127.2%3.7%Unavailable627.8%340.6%UnavailableUnavailable
Current ratio6.68x14.75x8.69x20.34x8.26x3.85x3.95x4.63x3.97x20.52x
Revenue YoY growth-82.3%Unavailable-670.2%-96.9%Unavailable-100.0%-61.5%UnavailableUnavailableUnavailable
Net margin-487.1%0.1%Unavailable-2151.7%-3.9%Unavailable-7883.7%-2724.1%UnavailableUnavailable
R&D / revenue434.3%65.7%Unavailable1711.4%47.5%Unavailable4526.5%1510.3%UnavailableUnavailable
CapEx / revenueUnavailable0.8%Unavailable26.8%0.0%UnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailable7.5%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open LPCN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-10View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.